ZA966148B - Novel formulation. - Google Patents

Novel formulation.

Info

Publication number
ZA966148B
ZA966148B ZA9606148A ZA966148A ZA966148B ZA 966148 B ZA966148 B ZA 966148B ZA 9606148 A ZA9606148 A ZA 9606148A ZA 966148 A ZA966148 A ZA 966148A ZA 966148 B ZA966148 B ZA 966148B
Authority
ZA
South Africa
Prior art keywords
novel formulation
formulation
novel
Prior art date
Application number
ZA9606148A
Other languages
English (en)
Inventor
Graham Stanley Leonard
David Philip Elder
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA966148(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA966148B publication Critical patent/ZA966148B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polyurethanes Or Polyureas (AREA)
ZA9606148A 1995-07-20 1996-07-19 Novel formulation. ZA966148B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation

Publications (1)

Publication Number Publication Date
ZA966148B true ZA966148B (en) 1998-01-19

Family

ID=10777960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606148A ZA966148B (en) 1995-07-20 1996-07-19 Novel formulation.

Country Status (41)

Country Link
EP (2) EP0839039B2 (xx)
JP (2) JP3922392B2 (xx)
KR (1) KR100468351B1 (xx)
CN (2) CN1282456C (xx)
AP (1) AP1052A (xx)
AR (1) AR003463A1 (xx)
AT (1) ATE253361T1 (xx)
AU (1) AU6659196A (xx)
BG (1) BG64076B1 (xx)
BR (1) BR9609857A (xx)
CA (2) CA2227298C (xx)
CY (1) CY2408B1 (xx)
CZ (1) CZ294110B6 (xx)
DE (1) DE69630603T3 (xx)
DK (1) DK0839039T4 (xx)
DZ (1) DZ2074A1 (xx)
EA (2) EA003775B1 (xx)
EG (1) EG23934A (xx)
ES (1) ES2208757T5 (xx)
GB (1) GB9514842D0 (xx)
HK (1) HK1010494A1 (xx)
HU (1) HU228853B1 (xx)
IL (1) IL122940A0 (xx)
MA (1) MA23942A1 (xx)
MX (1) MX9800571A (xx)
MY (1) MY141373A (xx)
NO (1) NO315637B1 (xx)
NZ (1) NZ315006A (xx)
OA (1) OA10652A (xx)
PE (1) PE16098A1 (xx)
PL (1) PL184987B1 (xx)
PT (1) PT839039E (xx)
RO (1) RO119119B1 (xx)
SI (1) SI0839039T2 (xx)
SK (1) SK284117B6 (xx)
TR (1) TR199800077T1 (xx)
TW (1) TW464513B (xx)
UA (1) UA68328C2 (xx)
UY (3) UY24288A1 (xx)
WO (1) WO1997003670A1 (xx)
ZA (1) ZA966148B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
KR100543614B1 (ko) 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
CA2367402C (en) 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
CN1874767A (zh) 2003-10-29 2006-12-06 惠氏公司 包含aplindore和其衍生物的缓释药物组合物
CA2556216A1 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
US20090130206A1 (en) * 2006-05-09 2009-05-21 Umesh Nandkumar Khatavkar Controlled Release Compositions of an Antidepressant Agent
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
WO2009035652A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
TW201010743A (en) 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
MX2012002199A (es) * 2009-08-24 2012-03-16 Lundbeck & Co As H Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
WO2014009152A1 (en) * 2012-07-09 2014-01-16 Unilever N.V. A photoprotective personal care composition
CN103550182B (zh) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
JP3064417B2 (ja) * 1990-08-21 2000-07-12 セラテック,インコーポレイテッド 放出制御性製剤及び方法
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
EP0720478A1 (en) * 1991-05-07 1996-07-10 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
EP0654263B1 (en) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release

Also Published As

Publication number Publication date
EA003508B1 (ru) 2003-06-26
DE69630603D1 (de) 2003-12-11
RO119119B1 (ro) 2004-04-30
MX9800571A (es) 1998-04-30
UY26242A1 (es) 2001-01-31
GB9514842D0 (en) 1995-09-20
PE16098A1 (es) 1998-04-16
SI0839039T2 (sl) 2007-10-31
UA68328C2 (en) 2004-08-16
EP0839039A1 (en) 1998-05-06
MY141373A (en) 2010-04-16
CA2445678C (en) 2009-11-24
JP2006265258A (ja) 2006-10-05
AP1052A (en) 2002-03-21
CN1515257A (zh) 2004-07-28
PT839039E (pt) 2004-03-31
EA003775B1 (ru) 2003-08-28
BG102259A (en) 1998-09-30
AR003463A1 (es) 1998-08-05
HUP9900299A3 (en) 1999-11-29
EG23934A (en) 2008-01-14
ES2208757T3 (es) 2004-06-16
PL324553A1 (en) 1998-06-08
DK0839039T4 (da) 2007-10-08
CN1195986A (zh) 1998-10-14
HUP9900299A2 (hu) 1999-09-28
PL184987B1 (pl) 2003-01-31
DK0839039T3 (da) 2004-03-08
DE69630603T3 (de) 2008-01-03
NO315637B1 (no) 2003-10-06
TR199800077T1 (xx) 1998-05-21
NZ315006A (en) 2000-01-28
AU6659196A (en) 1997-02-18
SK284117B6 (sk) 2004-09-08
SI0839039T1 (en) 2004-04-30
NO980240D0 (no) 1998-01-19
MA23942A1 (fr) 1997-04-01
UY24288A1 (es) 1997-01-16
EP1382337A1 (en) 2004-01-21
CA2227298A1 (en) 1997-02-06
HU228853B1 (en) 2013-06-28
ES2208757T5 (es) 2007-12-16
EP0839039B1 (en) 2003-11-05
OA10652A (en) 2002-09-18
NO980240L (no) 1998-01-20
ATE253361T1 (de) 2003-11-15
HK1010494A1 (en) 1999-06-25
CZ294110B6 (cs) 2004-10-13
KR19990029076A (ko) 1999-04-15
CN1282456C (zh) 2006-11-01
SK5398A3 (en) 1998-07-08
CA2227298C (en) 2003-12-09
CZ18398A3 (cs) 1998-06-17
BG64076B1 (bg) 2003-12-31
EA200100022A1 (ru) 2001-06-25
KR100468351B1 (ko) 2005-03-16
EP0839039B2 (en) 2007-06-06
CA2445678A1 (en) 1997-02-06
CN1117567C (zh) 2003-08-13
JP3922392B2 (ja) 2007-05-30
DE69630603T2 (de) 2004-09-23
BR9609857A (pt) 1999-03-16
IL122940A0 (en) 1998-08-16
AP9801177A0 (en) 1998-01-31
TW464513B (en) 2001-11-21
WO1997003670A1 (en) 1997-02-06
JPH11509539A (ja) 1999-08-24
UY24436A1 (es) 2001-08-27
DZ2074A1 (fr) 2002-07-22
CY2408B1 (en) 2004-09-10
EA199800140A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
ZA966148B (en) Novel formulation.
ZA967084B (en) Cement formulation.
ZA967315B (en) Biphenylamides.
ZA962338B (en) Oral 2-methyl-thieno-benzodiazepine formulation.
ZA9610858B (en) Heteroclyclic compounds.
ZA965190B (en) Pharmaceutical composition.
MX213417B (es) Fenilpiridazinonas.
EP0634459A3 (de) Formulierungen.
ZA967034B (en) Pharmaceutical compositions.
ZA966075B (en) Protein formulation.
ZA968250B (en) Cosmetic composition.
ZA964433B (en) Cosmetic composition.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA965505B (en) Novel compounds.
ZA967546B (en) Pharmaceutical formulation.
ZA961955B (en) Indazolecarboxamides.
ZA967420B (en) Hand cleanser.
ZA964872B (en) Sunscreen compositions.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA968081B (en) Pharmaceutical composition.
ZA96796B (en) Transdermal formulation.
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA966399B (en) Endothelin-receptor-antagonists.
ZA964560B (en) Anit-viral compounds.
ZA966933B (en) Endothelin-receptor-antagonists.